UNSPSC 51385610: Salicylsalicylic acid or salsalate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9MO595C9I, chemically known as salicylic acid, salicylate but generally known as salsalate, which bears US NIH Compound Identifier 5161. European Medicines Agency schedules Salsalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10434MIG.

UNSPSC 51385610 Salicylsalicylic acid or salsalate is a Commodity code that state and local procurement offices tag to pharmaceutical and medical supply acquisitions, though recent opportunities under this code show limited alignment with the nominal taxonomy scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—reflects a broader pattern in which state and local health departments and county public health agencies procure emergency medical supplies and harm-reduction pharmaceuticals through competitive bidding rather than sole-source or cooperative-purchasing vehicles. The issuing bodies acquiring under this code span county health departments and municipal public health programs, with procurement structured through traditional IFB notice types requiring fixed pricing, quarterly delivery schedules, and standard compliance certifications including drug-free workplace, E-Verify, and worker and general liability insurance.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement included a two-year initial term with a one-year renewal option and was potentially FEMA-funded, triggering federal compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. The limited recent-opportunity record under this commodity code suggests either low transaction volume or misalignment between the code's nominal pharmaceutical scope and actual state and local buying patterns; the Naloxone solicitation sits as the sole recent activity captured.